Why FDA Approval for Pfizer's COVID Vaccine Would Be a Slam Dunk For the Long Run

Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX) have filed for U.S. Food and Drug Administration (FDA) approval for their COVID-19 vaccine that has already been given to millions of Americans after receiving Emergency Use Authorization (EUA). In this Motley Fool Live video recorded on May 17, healthcare and cannabis bureau chief Corinne Cardina and Motley Fool contributor Keith Speights discuss why this FDA approval could basically be a slam dunk.